Core Insights - Biotech and natural resources funds were the top performers in the ALPS ETFs lineup for 2025, each achieving returns exceeding 45% [1] - The ALPS Medical Breakthroughs ETF (SBIO) specifically recorded significant gains, contributing to the overall strong performance of biotech funds [1] Performance Summary - Biotech funds delivered returns above 45%, indicating robust growth in the sector [1] - Natural resources funds also matched this performance, highlighting a strong interest and investment in these areas [1]

The ALPS Medical Breakthroughs ETF (SBIO) is trading close to its 52-week high of $51.87 after surging 10.51% in November, powered by a wave of positive clinical trial data and renewed merger activity in small- and midcap biotech companies, according to research from SS&C ALPS Advisors. The biotech ETF outpaced the Nasdaq Biotechnology Index's 8.5% November gain as investors rotated into smaller companies with drugs in late-stage development. SBIO attracted $19.54 million in net inflows during the past mont ...